Machine Learning for Cardiovascular Disease Prediction

Contents

Introduction

Problem Statement

Cardiovascular diseases (CVDs) continue to represent the most significant public health burden globally, causing an estimated 19.8 million deaths in 2022, according to the World Health Organization. These diseases encompass a wide range of life-threatening conditions, including coronary artery disease, heart failure, arrhythmia, and stroke. Alarmingly, CVDs are not only the leading cause of death in high-income countries but are also rapidly rising in low- and middle-income regions, where over 75% of cardiovascular deaths occur.

Despite notable advances in medical technology and therapeutic interventions, early diagnosis of CVD remains a pervasive challenge. Conventional diagnostic methods such as echocardiography, coronary angiography, stress testing, and CT angiography are effective but often come with substantial limitations. These procedures are typically expensive, resource-intensive, and require specialist infrastructure and trained personnel. As a result, they are largely inaccessible in remote, under-resourced, or rural areas where timely identification of cardiovascular risk is critically needed.

Moreover, many CVDs progress silently and remain asymptomatic in early stages, only becoming clinically apparent when damage is irreversible or life-threatening. This delay in detection significantly reduces the effectiveness of preventive strategies and increases both the personal and societal burden of the disease. Misdiagnosis or late diagnosis often results in avoidable hospitalizations, premature deaths, and substantial healthcare costs.

The core challenges this project addresses is the absence of an accessible, timely, affordable, and accurate diagnostic solution that can facilitate early detection and personalized risk prediction of cardiovascular diseases. By leveraging routinely available patient health data including demographic information, clinical measurements, and symptoms, this study aims to develop a machine learning-based predictive system capable of delivering rapid and interpretable cardiovascular risk assessments. Such a tool has the potential to augment clinical decision-making, especially in primary care and low-resource environments, and enable preventive interventions before critical deterioration occurs.

Background and Context

Cardiovascular diseases (CVDs) encompass a wide spectrum of disorders that impair the structure and function of the heart and vascular system, including conditions such as arrhythmias, cardiomyopathies, congenital heart defects, and peripheral artery disease. While the clinical manifestations may vary, these conditions share a common underlying pathology: progressive vascular dysfunction and organ strain, often compounded by modifiable risk factors such as smoking, poor diet, physical inactivity, and unmanaged stress.

One of the defining challenges of CVDs is their clinical latency. Many individuals remain unaware of their cardiovascular risk until they experience acute events such as myocardial infarction or stroke. This latency stems from the fact that physiological changes like arterial plaque buildup, blood pressure elevation, or impaired ventricular function occur gradually and often without noticeable symptoms. By the time clinical symptoms arise, significant damage may already be irreversible or require invasive interventions. This makes early risk stratification and proactive care planning essential.

In parallel, the healthcare industry is undergoing a digital transformation, where data-driven decision-making is becoming integral to improving outcomes. In this context, machine learning (ML) has emerged as a powerful tool capable of enhancing cardiovascular care by identifying patterns that may not be evident through traditional statistical methods or human judgment alone. Unlike conventional models that rely on limited feature engineering, ML algorithms can automatically learn from high-dimensional, multi-source datasets, incorporating information from wearables, electronic health records (EHRs), real-time biometric monitoring, and population-level data.

Importantly, ML systems can continuously improve as more data becomes available, allowing dynamic adaptation to emerging clinical trends. By providing predictive insights on an individual's likelihood of developing CVD, these systems can support clinicians in early triage, personalized risk management, and targeted lifestyle interventions, especially in settings where cardiology expertise may be scarce. Thus, integrating ML into cardiovascular risk prediction represents a significant advancement in delivering proactive, equitable, and scalable healthcare solutions. The integration of ML in digital health platforms has demonstrated substantial potential in improving early diagnosis and care delivery efficiency (Topol, 2019).

Importance

Healthcare Burden

CVDs significantly increase healthcare costs and reduce workforce productivity globally, creating a substantial economic and societal impact.

Early Interventions

Predictive analytics models are crucial for the early identification of individuals at risk, allowing for timely interventions that can prevent the onset or mitigate the severity of CVD.

Inefficiency in Current practices

Existing diagnostic methods often require specialized personnel, complex equipment, and extended analysis periods, limiting widespread and timely adoption.

Digital Health Opportunity

The growing prevalence of electronic health records (EHRs), telemedicine platforms, and wearable health technologies creates an unprecedented opportunity for data-driven, real-time disease prediction and management.

Personalize Healthcare

By utilizing predictive models, healthcare providers can develop personalized healthcare plans based on individual risk profiles, incorporating lifestyle changes and tailored monitoring.

Resource Optimization

Predictive analytics identifies high-risk individuals, enabling healthcare systems to allocate resources more efficiently and focus interventions where they are most needed.

Improved Patient Outcomes

Machine learning models improve the accuracy of diagnoses and the effectiveness of prevention strategies, thereby enhancing overall patient outcomes.

Business Model Analysis (BMA)

The proposed predictive model will be commercialized through a software-as-a-service (SaaS) model, providing scalable and cost-effective access to cardiovascular risk prediction tools for healthcare institutions. The platform will primarily target hospitals, primary care clinics, telemedicine providers, and diagnostic labs, offering a secure, cloud-based interface that integrates seamlessly with existing electronic health record (EHR) systems.

Revenue will be generated through a tiered subscription model, where larger institutions pay based on patient volume and feature access, while individual practitioners and small clinics can access a freemium version with core prediction capabilities. Additional revenue streams may come from strategic partnerships with wearable device manufacturers and health insurers seeking early risk screening solutions.

The key value proposition lies in reducing misdiagnoses, improving preventive care, and optimizing resource allocation, ultimately lowering treatment costs while enhancing patient outcomes. These benefits create strong economic, clinical, and ethical incentives for adoption at scale.

Data Characteristics and the 4 V’s

The dataset used in this project is a structured clinical dataset combining records from Cleveland and Hungarian heart disease studies. It contains 1,190 records and 14 variables, including both numeric features (e.g., age, cholesterol, resting blood pressure) and categorical features (e.g., sex, chest pain type, ST slope).

- **Volume**: Moderate-sized dataset suitable for prototype model training and testing.
- **Variety**: Includes a mix of continuous, ordinal, and nominal data types relevant to cardiovascular health.
- **Velocity**: The data is static but could be adapted for real-time streaming in the future with integration from wearable devices.
- **Veracity**: The dataset is relatively clean, with consistent formatting, minimal missing values, and clear semantics. Minor transformations (e.g., normalization and column renaming) were applied to standardize the data for modeling.

Platforms, Software, and Tools

The data preprocessing, visualization, and analysis were performed entirely in R, leveraging widely used libraries such as `dplyr`, `ggplot2`, and `readr` for cleaning, exploration, and transformation. These tools are ideal for structured health datasets and provide transparent, reproducible workflows. In future expansions, the project can be scaled to include real-time pipelines using platforms such as AWS for storage and deployment, and integration with web dashboards using Shiny or APIs for clinical usability.

Proposed Analytical Techniques

Two supervised learning methods are proposed for building the heart disease risk prediction model:

- **Logistic Regression**: Suitable for binary classification problems, logistic regression offers interpretable coefficients that can help identify key predictors of cardiovascular disease. It's ideal for baseline modeling and clinical explainability.
- **Random Forest**: A powerful ensemble method that builds multiple decision trees and aggregates their predictions. It handles nonlinear relationships well and provides feature importance scores, which can aid in identifying the most influential health indicators.

The model performance will be evaluated using accuracy, precision, recall, and ROC-AUC, ensuring both discriminative power and clinical reliability. Explainability techniques such as SHAP and LIME will be considered to support clinician trust and transparency.

Demonstration and Exploratory Data Analysis (EDA)



Figure 1 Distribution of the target variable (Heart Disease Yes/No)

Figure 1 Visualizes the distribution of the target variable. The target variable is balanced, with slightly more individuals diagnosed with heart disease (1) than those without (0).
There are about 630 heart disease cases and 560 non-cases, making this dataset suitable for binary classification without major class imbalance issues.

Figure 2 shows age, cholesterol, and max heart rate are approximately normally distributed. Oldpeak shows a sharp spike around 0, indicating most patients had minimal ST depression. Resting_bp_s has a somewhat symmetrical but compact distribution after scaling. This distributional insight justifies scaling and motivates feature engineering for skewed variables like oldpeak.



Figure 2 Histogram of numerical features



Figure 3 Proportion of heart disease across sex

Figure 3 shows that Males (1) are more likely to have heart disease than females. Chest pain type: Type 4 has the highest proportion of disease cases. Individuals with high sugar (1) are more likely to have heart disease.

Strongly associated with angina (1) mostly have heart disease. ST slope = 0 or 2 shows higher disease proportions; 1 has lower.

These categorical features show clear class separability.

Figure 4 Boxplots illustrate the variation in numeric variables between patients with and without heart disease. Age and oldpeak values are higher in patients with heart disease. Cholesterol and max heart rate are generally lower in disease-positive individuals. Resting_bp_s shows overlapping distributions, less discriminative. This supports using variables like oldpeak, age, and max_heart_rate for model training.



Figure 4 Boxplots of Numeric Variables by Heart Disease Status



Figure 5 Correlation Heatmap of Numeric Features

Figure 5 shows most features are weakly correlated (|r| < 0.4), suggesting low multicollinearity. Age and resting_bp_s show modest correlation (~0.26). Max heart rate is negatively correlated with age and oldpeak, indicating that older patients tend to have lower max heart rates.
This independence makes multiple variables viable inputs for predictive modeling.

Figure 6 Density plots compare the distributions of numeric features for each target group.
heart disease patients tend to be older and have higher oldpeak, while those without it show higher max heart rates.
This visualization highlights variable distributions conditioned on class labels.



Figure 6 Density Plots by Target Group



Figure 7 The bar chart shows the absolute counts of patients with different chest pain types, grouped by target class.
Type 4 chest pain is significantly more common among patients with heart disease.
This reinforces its importance as a predictive feature in classification models.

Figure 7 Chest Pain Type by Heart Disease

Predictive Modeling Results

Both models were trained on 80% of the dataset and evaluated on the remaining 20%. ***Figure 8*** shows that logistic regression achieved 82.8% accuracy, with interpretable coefficients identifying key predictors. Random Forest achieved 92.4% accuracy, with significantly fewer misclassifications. ***Figure 9*** show the Feature importance from Random Forest indicated ST_slope, chest_pain_type, and max_heart_rate as top predictors. Based on performance and interpretability needs, Random Forest is preferred for deployment, with future integration of SHAP for explainability.



Figure 8 Comparison of accuracy and classification performance



Figure 9 Feature Importance from Random Forest Model

Standard for Data Science Process, Data Governance and Management

Standards Used in the Data Science Process

This project adopts the CRISP-DM framework as a guiding methodology for ensuring a robust, structured, and iterative data science lifecycle (Wirth & Hipp, 2000). CRISP-DM includes the following six phases:

1. Business Understanding – Defined the clinical and public health challenge of cardiovascular disease misdiagnosis and its cost to society and health systems.
2. Data Understanding – Explored the statistical structure, distribution, and limitations of the selected dataset.
3. Data Preparation – Conducted standard preprocessing steps including cleaning, encoding, normalization, and type conversions consistent with clinical data workflows.
4. Modeling – Applied logistic regression and random forest algorithms using reproducible R code in accordance with modeling best practices.
5. Evaluation – Employed performance metrics such as accuracy, recall, and ROC-AUC, while ensuring model generalizability and fairness.
6. Deployment – Developed a prototype Shiny application to simulate clinical usage scenarios where healthcare professionals can input patient data and receive decision support with interpretability.

The process aligns with FAIR principles (Findable, Accessible, Interoperable, Reusable) by ensuring data and models are structured, well-labeled, transparent, and modular enough for clinical extension and integration into Electronic Health Records (EHR) systems (Wilkinson et al., 2016).

Data Governance and Management

To support ethical, secure, and clinically reliable use of health-related data, the project implements the following governance practices:

- Data Accessibility and Provenance: The dataset originates from open-access repositories (e.g., Kaggle) with no personal identifiers or sensitive attributes. All data used is anonymized and suitable for academic and prototyping use.
- Data Security and Compliance: All operations were conducted locally within a secure RStudio environment. For future clinical deployment, the system design will conform to ISO/IEC 27001 standards for information security management, ensuring controlled access, auditability, and risk mitigation (ISO, 2013).
- Confidentiality and Privacy: No personal health information (PHI) is processed or stored. The deployed Shiny application is non-persistent and does not transmit data externally, aligning with Australian Privacy Principles (APPs) and GDPR regarding privacy by design and user data minimization.

Ethical AI Practices:

- Incorporates explainability techniques (e.g., variable importance, interpretable models) to foster transparency and clinical trust.
- Follows principles of fairness and accountability by monitoring potential bias across gender, age, and chest pain types.
- The interface includes disclaimers to reinforce that the tool is intended for decision support, not diagnosis.

Clinical Readiness:

- The tool is built with integration-readiness, allowing future alignment with HL7 FHIR (Fast Healthcare Interoperability Resources) standards for EHR compatibility.
- User interface and output design follow human-centered design principles to support ease of use for healthcare professionals.
- These standards and governance practices position the project for ethical real-world deployment, while maintaining scientific rigor and legal compliance.

References

ISO/IEC. (2013). *Information technology – Security techniques – Information security management systems – Requirements (ISO/IEC 27001:2013)*. International Organization for Standardization.

Liu, T., Krentz, A. J., Lu, L., & Curcin, V. (2025). Machine learning-based prediction models for cardiovascular disease risk using electronic health records data: Systematic review and meta-analysis. *European Heart Journal – Digital Health*, 6(1), 7–17. https://academic.oup.com/ehjdh/article/6/1/7/7845948

Loh, D. R., Yeo, S. Y., Tan, R. S., Gao, F., & Koh, A. S. (2021). Explainable machine learning predictions to support personalized cardiovascular risk management. *European Heart Journal – Digital Health*, 2(4), 576–578. https://doi.org/10.1093/ehjdh/ztab096

Phillips, M., & Tran, B. (2024). Ethical and bias considerations in artificial intelligence/machine learning applications in surgery. *Surgical Clinics of North America*, 104(1), 65–75. https://www.sciencedirect.com/science/article/pii/S0893395224002667

Pozzi, G. (2023). On the ethics of algorithmic decision-making in healthcare. *Journal of Medical Ethics*, 49(8), 573–580. https://jme.bmj.com/content/49/8/573

Sun, J., & Liu, X. (2025). An explainable artificial intelligence (XAI) methodology for heart disease prediction. *International Journal of Current Science Research and Review*, 8(2), 503–512. https://doi.org/10.47191/ijcsrr/V8-i2-28

Topol, E. (2019). *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again*. Basic Books.

Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. *Scientific Data*, 3, Article 160018. https://doi.org/10.1038/sdata.2016.18

Wirth, R., & Hipp, J. (2000). CRISP-DM: Towards a standard process model for data mining. In *Proceedings of the 4th International Conference on the Practical Applications of Knowledge Discovery and Data Mining* (pp. 29–39).

Xia, B., Innab, N., Kandasamy, V., Ahmadian, A., & Ferrara, M. (2024). Intelligent cardiovascular disease diagnosis using deep learning enhanced neural network with ant colony optimization. *Scientific Reports*, 14(1), Article 1216. https://doi.org/10.1038/s41598-024-71932-z

Yu, H., & Lee, C. H. (2025). Transforming cardiovascular risk prediction: A review of machine learning in cardiovascular disease prevention. *Life*, 15(1), Article 94. https://doi.org/10.3390/life15010094